Pressemitteilung BoxID: 334910 (Roche Diagnostics Deutschland GmbH)
  • Roche Diagnostics Deutschland GmbH
  • Sandhofer Str. 116
  • 68305 Mannheim
  • Ansprechpartner
  • Ulrich Schwoerer
  • +1 (203) 871-2300

454 Sequencing Study Unravels the Hidden Genomic Complexity of the Giant Mimivirus

(PresseBox) (Branford, CT, ) A study published online today in the journal Genome Research offers surprising new clues into the genomic complexity of the giant Mimivirus, the largest known virus in the world. Previous studies have shown that unlike most viruses, the Mimivirus has more genes than many bacteria and performs functions that normally occur only in cellular organisms. The results of the most recent study, led by a team from the Structural and Genomic Information Laboratory at the Mediterranean Institute of Microbiology in Marseille, France, suggest that the Mimivirus is even more complex than previously thought. Using the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), the researchers performed the first ever viral transcriptome analysis by deep sequencing RNAs expressed by infected amoebas throughout the Mimivirus replication cycle (1). Unexpectedly, the analysis revealed 75 new genes, including 26 producing non-coding RNAs. The existence, and so far unknown function, of these additional genes in the already plethoric Mimivirus genome could radically change the current understanding of the way large viruses operate.

Since the discovery and deciphering of its genome in 2004, the giant Mimivirus has blurred the traditional boundaries between viruses and cellular organisms, spurring debate between virologists and evolutionary biologists. In a quest to fully characterize the Mimivirus transcriptome and obtain new insights into its gene and protein functions, the researchers turned to the Genome Sequencer FLX System. “Not only were we able to confirm the 910 previously predicted protein-coding genes, but we also identified 75 novel genes in the Mimivirus,” explained Jean-Michele Claverie and Chantal Abergel, senior authors of the study. “The long reads generated by the GS FLX System were critical for the assembly of full length transcripts, identification of polycistronic mRNA and for the discovery of short transcripts, since the 5’ and 3’ tags were contained within a single read.”

Sequence mapping also allowed the precise delineation of most promoter regions and the identification of the sequence motif governing the early versus late expression of Mimivirus genes. Excitingly, the study revealed a new promoter element correlating with late gene expression that is also prominent in Sputnik, the recently described Mimivirus “virophage”.

Moving forward, the researchers plan to perform similar viral transcriptome analysis in the presence and absence of various inhibitors, and with other amoeba strains that have different sensitivity to the Mimivirus. Since recent metagenomics studies suggest that Mimivirus could be the prototype of numerous marine viruses infecting a variety of planktonic micro-organisms, a specific program is devoted search for the Mimivirus’ marine relatives in the ongoing international TARA-Oceans expedition.

“We are pleased to see continued widespread adoption of 454 Sequencing systems in virology research,” said Ulrich Schwoerer, Head of Global Marketing at 454 Life Sciences. “This particular study demonstrates, for the first time, the unique capabilities of the technology for comprehensive transcriptome analysis of viral genomes. We are excited to follow the team’s continued work in this field.”

For more information on 454 Sequencing Systems, visit

(1) Legendre et al. mRNA Deep Sequencing Reveals 75 New Genes and a Complex Transcriptional Landscape in Mimivirus. Genome Research (2010). ePub April 1.

For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, 454 SEQUENCING, and GS FLX are trademarks of Roche.
Other brands or product names are trademarks of their respective holders.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: